Asset

GDC-0917

Curis Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (1)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT01908413phase1terminated2013-07-012015-03-01Curis, Inc.Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)